Skip to main content
. 2021 Jan 21;11:2062. doi: 10.1038/s41598-021-81629-2

Figure 2.

Figure 2

Longitudinal analysis SARS-CoV-2 neutralizing antibodies in patients with varying severity of COVID-19. SARS-CoV-2 NAbs were measured in those with severe (n = 6), moderate (n = 5) and mild/asymptomatic illness (n = 13) and also those who had mild illness but with prolonged shedding of the virus (n = 21) (A). In order to assess the timing of the NAb responses at different time point, these antibodies were measured in patients with severe pneumonia (n = 10), moderate illness (n = 19), mild illness (n = 150) and prolonged shedding (n = 82). The NAbs levels were determined in this larger cohort of individuals during the first 3 weeks and during week 4 to 8 of illness (B). The black dotted line indicates the cut-off value of a positive result.